Добро пожаловать в клуб

Показать / Спрятать  Домой  Новости Статьи Файлы Форум Web ссылки F.A.Q. Логобург    Показать / Спрятать

       
Поиск   
Главное меню
ДомойНовостиСтатьиПостановка звуковФайлыДефектологияКнижный мирФорумСловарьРассылкаКаталог ссылокРейтинг пользователейЧаВо(FAQ)КонкурсWeb магазинШкольникамКарта сайта

Поздравляем!
Поздравляем нового Логобуржца Фарида со вступлением в клуб!

Реклама

КНИЖНЫЙ МИР

Drug Design At The Peroxisome Proliferator-Activated Receptor   Julienne Ciantar,Claire Shoemake and Lilian M. Azzopardi

Drug Design At The Peroxisome Proliferator-Activated Receptor

168 страниц. 2013 год.
LAP Lambert Academic Publishing
The Peroxisome Proliferator-Activated Receptor Gamma (PPAR?) agonist Rosiglitazone, has recently been withdrawn from the European market and its use has been restricted in the US due to its undesirable effects which were considered to outweigh its benefits. This study explores the two agonist bound conformations of the PPAR?, as exemplified by its binding to Rosiglitazone and that to Farglitazar. Furthermore, it evaluates whether they should be targeted separately in the context of drug design studies. The binding modalities of Rosiglitazone and Farglitazar were studied in great detail and a series of molecules capable of agonist activity at the PPAR? have been designed, with the potential to act as leads in a drug design process.
 
- Генерация страницы: 0.04 секунд -